Hui Liu, MD, PhD

Sun Yat-Sen University Cancer Center
Guang Dong Province, Guangdong

NAME: Professor Hui Liu

EDUCATION/TRAINING

1. Personal Statement

I am a Radiation Oncologist who specializes in thoracic malignancies. I have a special interest in defining risk factors of radiation induced toxicities. I used to establish a model for predicting radiation pneumonitis after sterotactic ablative radiotherapy in patients with previous conventional thoracic radiotherapy. I am also committed to research in developing advanced radiation techniques that can help improve local control and assessments for patients suffering from lung cancer and esophageal cancer for appropriate therapies.

1. Positions and Honors

1998-1999, Medicine Internship, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China

1999-2003, Clinical Residency, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

2003-2008, Assistant Professor, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

2008-2014, Associate Professor, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

2015- , Professor, Deputy Chair, Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China

2010-2011, Visiting Scientist, Department of Radiation Oncology, The University of Texas MD Anderson Cancer, U.S.A.

2016-9, ITMIG Masaoka Award Best Oral Presentation

2017-7, member of The IASLC Staging and Prognostic Factors Committee (SPFC) 2017-8, PI and lead research associate of NRG-RTOG (main membership institute)

2017-10, member of ITMIG

2012-10, member of ASTRO

Disclosures:

• Employment: none
• Compensation: :Role Topic Description-End Date:
• Ownership: none
• Leadership: none

Presentation(s):

• 2197 - Online Adaptive MR-Guided Fractionated Stereotactic Radiotherapy for Brain Metastases in Patients with Non-Small Cell Lung Cancer (GASTO-1075)

  Sunday, September 29, 2024
  2:45 PM – 4:15 PM ET

• 189 - Hypofractionated Radiotherapy plus Concurrent Chemotherapy with or without Consolidation Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer (GASTO-1052)

  Monday, September 30, 2024
  10:55 AM – 11:05 AM ET